Eli Lilly and Company

Revaax Pharmaceuticals, LLC

Azevan Pharmaceuticals, Inc.

Gary A Koppel

Robin D Cooper

Russell L Barton

Robert F Bruns, Jr

Marvin J Miller

Lawrence J McShane

David C Hunden

Stephen L Briggs

Jeffrey J Skelton

Bruce Anthony Dressman

Stephen W Kaldor

William Leonard Scott

Mitchell I Steinberg

John Robert Rizzo

Michael O Chaney

Deborah L Guttman-Carlisle

George J Cullinan

Kennan Joseph Fahey

Ned D Heindel

Robin D G Cooper

G Davon Kennedy

Henry K Armour

Christophe D G Guillon

Robin E Offord

Robert R Chauvette

Keith Rose

Laurence J Nummy

Charles W Ashbrook

Gary V Kaiser

Joseph W Parton

Jesse R Bewley

Robert F Bruns

Shifang Lu

Christophe D Guillon

0-lactamyl alkanoic acids are described. Methods for treating various premenstrual disorders using or more &#x3b2;-lactamyl alkanoic acids are also described.

Beta-lactamylalkanoic acids for treating premenstrual disorders

Substituted 2-(azetidin-2-on-1-yl)alkoxyalkylalkanoic acids and 2-(azetidin-2-on-1-yl)arylalkylalkanoic acids, and analogs and derivatives thereof are described. Methods for using the described compounds, and pharmaceutical compositions thereof, to treat disease states responsive to antagonism of one or more vasopressin receptors are also described.

&#x3b2;-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists

Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists

A method for improving sexual function is described. A mammal suffering from sexual dysfunction or otherwise in need of enhanced sexual function is administered a compound selected from those that are capable of inhibiting the activity of &#x3b2;-lactams, penicillin-binding proteins, and carboxypeptidases. Such compounds, including particularly &#x3b2;-lactam ring-containing compounds, can be used to formulate pharmaceutical formulations useful for improving sexual function.

Neurotherapeutic treatment for sexual dysfunction

Administration of &#x3b2;-Lactam compounds, including &#x3b2;-lactam antibiotics and &#x3b2;-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidence inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.

Neurotherapeutic compositions and method

The treatment of neurological disorders using cephalosporin sulfoxide-containing and/or cephalosporin sulfone-containing compositions and pharmaceutical compositions including oral dosage forms that include cephalosporin sulfoxide and/or sulfone-containing compositions are described.

Oral neurotherapeutic cephalosporin sulfoxide and sulfone-containing compositions

Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin Vreceptor 

[object Object]

A method for improving sexual function is described. A mammal suffering from sexual dysfunction or otherwise in need of enhanced sexual function is administered a compound selected from those that are capable of inhibiting the activity of &#x3b2;-lactams, penicillin-binding protein, carboxypeptidase,. Such compounds, including particularly &#x3b2;-lactam ring-containing compounds, can be used to formulate pharmaceutical formulations useful for improving sexual function.

Therapeutic treatment for sexual dysfunction

Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin Vreceptor.

Administration of &bgr;-lactam compounds including &bgr;-lactam antibiotics and &bgr;-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.

Treatment of behavioral disorders with &bgr;-lactam compounds

Administration of clavulanic acid and related compounds at low dosages provides significant neurotropic effects in warm-blooded vertebrates evidenced by anxiolytic and anti-aggressive behavior and enhanced cognition believed to be mediated by inhibition of neurogenic enzyme activity. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.

Neurotherapeutic clavulanate composition and method

Non-peptidyl vasopressin V1A antagonists

Non-peptidyl vasopressin V1a antagonists

Administration of inhibitors of carboxypeptidase E provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior and enhanced cognition. Certain &bgr;-Lactam antibiotics, most significantly, certain 1-oxa-1-dethia cephems with blood brain barrier transport, exhibit potent therapeutic neurologic activity.

Neurotherapeutic use of carboxypeptidase inhibitors

Novel neuroprotectant methods are described. &bgr;-Lactamase inhibitors are used to prevent or reduce loss of neuronal cells and neuronal cell function in patients afflicted with or susceptible to disease states or conditions known to result in or cause neuronal tissue insult.

Use of &bgr;-lactamase inhibitors as neuroprotectants

Growing community of inventors

Indianapolis, IN, United States of America

Gary A Koppel